Health and Healthcare
Short Interest in Biotech Remains Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)
Published:
We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corp. (NASDAQ: CELG), Dendreon Corp. (NASDAQ: DNDN), Gilead Sciences Inc. (NASDAQ: GILD), Illumina Inc. (NASDAQ: ILMN), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Pharmacyclics Inc. (NASDAQ: PCYC), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and VIVUS Inc. (NASDAQ: VVUS). We also tracked the iShares Nasdaq Biotechnology (NASDAQ: IBB) against the group.
The short interest in biotech stocks is mixed, judging by the short interest changes between the October 15 and October 31 settlement dates. There were notable swings in shares sold short from Amgen, Biogen Idec, Celgene and Vertex. Short interest also was mixed in the previous period.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest fell 2.9% between October 15 and October 31 to 5.01 million shares. Days to cover dwindled to 2.3.
Amgen Inc. (NASDAQ: AMGN) saw short interest jump 12.8% to 15.01 million shares. That was the highest number of shares since March. Days to cover slipped to about three.
Arena Pharmaceuticals Inc. (NASDAQ: ARNA) short interest rose 7.4% to 50.94 million shares. That is the highest level this year. Short interest was more than 23% of the float.
Biogen Idec Inc. (NASDAQ: BIIB) shares sold short grew about 30% to 2.19 million, after declines in the previous two periods. Days to cover is about 1.5. But short interest is about 1% of the float.
Short interest in Celgene Corp. (NASDAQ: CELG) fell 11.5% to 4.66 million shares, its lowest level this year. Days to cover remains about two.
Dendreon Corp. (NASDAQ: DNDN) short interest ticked up 0.6% to 47.16 million shares. This was about 31% of the float. Days to cover is more than 14.
Gilead Sciences Inc. (NASDAQ: GILD) short interest increased 4.0% to 30.29 million shares. This was the fourth consecutive period of rising short interest.
Illumina Inc. (NASDAQ: ILMN) saw short interest rise 3.6% to 29.41 million shares. That was the eighth consecutive period of increasing short interest. Short interest rose to 24.3% of the float.
Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) shares sold short declined 3.2% to 5.91 million. Days to cover is less than five. Short interest slipped to 8.9% of the float.
Pharmacyclics Inc. (NASDAQ: PCYC) short interest retreated 2.5% to 4.29 million shares. That was the lowest level this year. Days to cover fell from about 12 in the previous period to about eight.
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) short interest fell 3.6% to 4.99 million shares, on the highest average daily volume since July. Shares sold short ticked down to 6.7% of the float.
Short interest in Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shrank 16.2% to 5.59 million shares. That was its lowest level since July. Days to cover rose to almost 2.5.
VIVUS Inc. (NASDAQ: VVUS) short interest was 4.1% higher to 17.63 million shares. Days to cover rose to about six. Short interest rose to 17.6% of the float.
To show how the sector has held up: the iShares Nasdaq Biotechnology (NASDAQ: IBB) ETF pulled back 7.3% to $131.87 during that period. Its current 52-week range is $92.15 to $148.54.
Trey Thoelcke
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.